---
title: "Shenzhen Neptunus Bioengineering Co.,Ltd. (000078.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000078.SZ.md"
symbol: "000078.SZ"
name: "Shenzhen Neptunus Bioengineering Co.,Ltd."
industry: "Health Care Distributors"
datetime: "2026-03-03T13:20:15.078Z"
locales:
  - [en](https://longbridge.com/en/quote/000078.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000078.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000078.SZ.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000078.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000078.SZ.md)


# Shenzhen Neptunus Bioengineering Co.,Ltd. (000078.SZ)

## Company Overview

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for hospitals, medical institutions, and drug retail institutions and distributors.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.neptunusbio.com](https://www.neptunusbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:11.000Z

**Overall: D (0.71)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 25 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.63% |  |
| Net Profit YoY | 29.92% |  |
| P/B Ratio | 4.85 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8872672934.14 |  |
| Revenue | 27376556511.13 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -49.97% | E |
| Profit Margin | -4.45% | D |
| Gross Margin | 8.98% | E |
| Revenue YoY | -15.63% | E |
| Net Profit YoY | 29.92% | B |
| Total Assets YoY | -12.91% | E |
| Net Assets YoY | -32.11% | E |
| Cash Flow Margin | -2247.04% | E |
| OCF YoY | -15.63% | E |
| Turnover | 0.93 | A |
| Gearing Ratio | 89.57% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shenzhen Neptunus Bioengineering Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.63%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "29.92%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.85",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8872672934.14",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "27376556511.13",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-49.97%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4.45%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "8.98%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-15.63%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "29.92%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.91%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-32.11%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-2247.04%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-15.63%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.93",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "89.57%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.00 | 20/25 | - | - | - |
| PB | 4.66 | 22/25 | 5.05 | 3.75 | 3.37 |
| PS (TTM) | 0.31 | 9/25 | 0.34 | 0.24 | 0.21 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | B | B |
| 02 | Jointown (600998.SH) | C | B | A | D | B | B |
| 03 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | B | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | B | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | B | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000078.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000078.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000078.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000078.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**